Clinical Trials on Liver Cancer in New Zealand

Total 9305 results

ABK Biomedical

Completed

Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC

Metastatic Colorectal Cancer | Liver Cancer | Hepatocellular Carcinoma Non-resectable

New Zealand
National Medical Research Council (NMRC), Singapore

Completed

Tamoxifen in Treating Patients With Primary Liver Cancer

Liver Cancer

New Zealand, Hong Kong, Indonesia, Malaysia, Pakistan, Singapore
Arrowhead Pharmaceuticals

Completed

Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH

Non-alcoholic Steatohepatitis

New Zealand
Hoffmann-La Roche
Tempest Therapeutics; Adagene Inc; Immune-Onc Therapeutics; NiKang Therapeutics...

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Advanced Liver Cancers

Korea, Republic of, Taiwan, United States, Israel, China, France, New Zealand
Dicerna Pharmaceuticals, Inc.

Withdrawn

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

Alpha 1-Antitrypsin Deficiency

New Zealand
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
University of Auckland, New Zealand

Completed

Profiling of Oncology Patients as Part of Clinical Care and Research (PROSPER)

Gynecologic Cancer

New Zealand
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Hepatitis C

New Zealand
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Hepatitis C Virus Infection

New Zealand
Assembly Biosciences

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults

Chronic Hepatitis B

New Zealand
National Medical Research Council (NMRC), Singapore

Completed

Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Liver Cancer

Singapore, Bangladesh, Thailand, Vietnam, Philippines, Indonesia, Korea, Republic of, Myanmar, New Zealand, Taiwan
Janssen Research & Development, LLC

Terminated

A Single and Multiple Ascending Dose Study of JNJ-64457744

Healthy | Hepatitis B, Chronic

New Zealand
Hoffmann-La Roche

Completed

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Early Breast Cancer

New Zealand
Hoffmann-La Roche

Completed

A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic, Healthy Volunteer

New Zealand
Novartis Pharmaceuticals

Terminated

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Hepatitis C

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Chronic Hepatitis b

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Assembly Biosciences

Completed

A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects

Chronic Hepatitis B

New Zealand
Trans Tasman Radiation Oncology Group
Fisher and Paykel Healthcare; Auckland City Hospital

Completed

Radiotherapy With Humidification in Head And Neck Cancer (RadioHum)

Cancer of the Head and Neck

New Zealand
Antipodean Pharmaceuticals, Inc.

Completed

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Chronic Hepatitis C

New Zealand
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Arrowhead Pharmaceuticals

Completed

Study of ARO-AAT in Normal Adult Volunteers

Alpha 1-Antitrypsin Deficiency

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Assembly Biosciences

Completed

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

New Zealand
Arrowhead Pharmaceuticals

Terminated

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Hepatitis B

New Zealand
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Chronic Hepatitis B

New Zealand
Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
Middlemore Hospital, New Zealand

Unknown

Comparing Diagnostic Yield Between R-EBUS Guided Cryo Biopsy Vs. CT Guided Biopsy for PPL (CT-CROP)

Lung Cancer

New Zealand
Gilead Sciences

Completed

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Nonalcoholic Steatohepatitis (NASH) | Primary Sclerosing Cholangitis (PSC)

United States, New Zealand
Provectus Pharmaceuticals

Completed

PV-10 Chemoablation of Recurrent Breast Carcinoma

Breast Cancer

New Zealand
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
University of Auckland, New Zealand
Waitemata District Health Board; Counties Manukau Health

Completed

Randomised Trial of Doppler-Optimised Fluid Balance in Elective Colectomy

Colorectal Cancer | Surgery | Perioperative Care | Colectomy

New Zealand
National Cancer Institute (NCI)

Completed

IMC-A12 in Treating Patients With Advanced Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Virion Therapeutics

Recruiting

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Chronic Hepatitis B

Hong Kong, New Zealand
Novira Therapeutics, Inc.

Completed

Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Chronic Hepatitis B

New Zealand
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States, New Zealand
Boston Scientific Corporation

Withdrawn

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases (Prometheus)

Liver Neoplasm | Metastatic Liver Cancer | Secondary Liver Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Liver Cancer

United States
National Cancer Institute (NCI)

Completed

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Aligos Therapeutics

Terminated

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Chronic Hepatitis B

United Kingdom, New Zealand
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Completed

Study of DCR-A1AT in Healthy Adult Volunteers

Alpha 1-Antitrypsin Deficiency

New Zealand, Sweden
University of Zurich
University Hospital, Strasbourg, France; University College London Hospitals; University Hospital, Essen and other collaborators

Completed

Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI) (MRevaluation)

Neoplasms

United Kingdom, Germany, Switzerland, United States, France, New Zealand
Eureka Therapeutics Inc.

Recruiting

T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3)

Hepatocellular Carcinoma | Liver Neoplasm | Metastatic Liver Cancer | Liver Cancer, Adult

United States
Arrow Therapeutics
DDS, Dundee; David Mutimer, Birmingham; Ed Gane, ACS New Zealand

Terminated

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (CP104)

Chronic Hepatitis C

New Zealand, United Kingdom
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States

3

Subscribe